Brussels to review biotech

Published: 1-Sep-2005


A European Commission paper on promoting life sciences and biotechnology in the European Union has indicated that Brussels will review administrative procedures regarding market approvals for biotech medicines.

This follows recommendations from an EU Competitiveness in Biotechnology Advisory Group: 'problems remain with the licensing of medicines derived from biotechnology. Some registration procedures used by the EMEA are both complex and expensive and may act as a major disincentive to the introduction of new products by SMEs (small and medium-sized businesses)'.

The Commission has recently been improving pharmaceutical industry administrative guidelines.

You may also like